Therapeutic strategies to combat antibiotic resistance

Brooks, Benjamin D.; Brooks, Amanda E.

doi:10.1016/j.addr.2014.10.027

Cited by 310 publications

(211 citation statements)

References 171 publications

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…60 In addition, a prolonged effective time can be achieved through the "combinatorial" method, which can effectively and significantly reduce the possibility of the development of resistance in bacteria. 61 The abovementioned advantages may unite in diverse combinations with different emphases in the process of actual application.…”

mentioning

confidence: 99%

The antimicrobial activity of nanoparticles: present situation and prospects for the future

Wang¹,

Hu²,

Shao³

2017

IJN

3,050

1,792

View full text Add to dashboard Cite

Nanoparticles (NPs) are increasingly used to target bacteria as an alternative to antibiotics. Nanotechnology may be particularly advantageous in treating bacterial infections. Examples include the utilization of NPs in antibacterial coatings for implantable devices and medicinal materials to prevent infection and promote wound healing, in antibiotic delivery systems to treat disease, in bacterial detection systems to generate microbial diagnostics, and in antibacterial vaccines to control bacterial infections. The antibacterial mechanisms of NPs are poorly understood, but the currently accepted mechanisms include oxidative stress induction, metal ion release, and non-oxidative mechanisms. The multiple simultaneous mechanisms of action against microbes would require multiple simultaneous gene mutations in the same bacterial cell for antibacterial resistance to develop; therefore, it is difficult for bacterial cells to become resistant to NPs. In this review, we discuss the antibacterial mechanisms of NPs against bacteria and the factors that are involved. The limitations of current research are also discussed.

show abstract

mentioning

confidence: 99%

The antimicrobial activity of nanoparticles: present situation and prospects for the future

Wang¹,

Hu²,

Shao³

2017

IJN

3,050

1,792

View full text Add to dashboard Cite

show abstract

“…According to several studies, including those from the Infectious Diseases Society of America (IDSA), after the year 1983 there was a substantial reduction in the number of new antibiotics released on the market [16,17]. This lack of investment involves directly the pharmaceutical companies that prefer to invest in medications for chronic diseases rather than drugs to treat diseases that may be quickly cured.…”

Section: Bacterial Resistance: a Really Big Issue To Take Seriouslymentioning

confidence: 99%

Biofilm: An Important Bacterial Feature Still to Deal With

Novais

Abreu

Castro

2016

Journal of Life Sciences Research

View full text Add to dashboard Cite

Currently, the bacterial infections are one of the main causes of death worldwide and a public health problem for most governments. In this scenario, virulence factors are of importance, including the capacity of forming biofilm. The ability of producing biofilms is directly involved in bacterial pathogenicity and hugely worse the risk of death due to a bacterial infection. This feature allows the bacteria to colonize different surfaces (e.g. Medical devices), and causes several complications, especially in nosocomial infections. This work reviewed biolfim producing mechanisms, the relation with resistance process and the problems associated to biofilms-affected-medical devices.

show abstract

“…Alternatively, bacteria can also gain resistance from other resistant strains via horizontal gene transfer (HGT) (plasmid, transposons, integrons, etc.) during conjugation-"acquired resistance" [15,16].…”

Section: Mechanism Of Resistancementioning

confidence: 99%